Results for Nucleic Acids ( 3456 )
- From: €7,284.00
DNA was prepared from cell line WM1361A. WM1361A is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous PTEN deletion and is wild type for BRAF, c-KIT, and CDK4. WM1361A cells produce xenograft tumors when injected into immunocompromised mice.
- From: €2,175.00
Total RNA was prepared from cell line WM1361A. WM1361A is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous PTEN deletion and is wild type for BRAF, c-KIT, and CDK4. WM1361A cells produce xenograft tumors when injected into immunocompromised mice.
- From: €3,630.00
Total RNA was prepared from cell line WM1361A. WM1361A is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous PTEN deletion and is wild type for BRAF, c-KIT, and CDK4. WM1361A cells produce xenograft tumors when injected into immunocompromised mice.
- From: €7,284.00
Total RNA was prepared from cell line WM1361A. WM1361A is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61R mutation at position 61 in the N-RAS gene. The Q61R is the most common NRAS mutation found in melanoma that is thought to occur due to UV and radiation exposure. This mutation leads to production of a constitutively active N-RAS protein that directs cells to grow and divide constantly. This cell line also expresses PTEN loss of function including hemizygous PTEN deletion and is wild type for BRAF, c-KIT, and CDK4. WM1361A cells produce xenograft tumors when injected into immunocompromised mice.
- From: €2,175.00
DNA was prepared from cell line WM1366. WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.
- From: €3,630.00
DNA was prepared from cell line WM1366. WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.
- From: €7,284.00
DNA was prepared from cell line WM1366. WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.
- From: €2,175.00
Total RNA was prepared from cell line WM1366. WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.
- From: €3,630.00
Total RNA was prepared from cell line WM1366. WM1366 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a right forearm in a 79-year-old male with stage IV superficial spreading melanoma. WM1366 cells produce xenograft tumors when injected into immunocompromised mice. This cell line features a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). The role of N-RAS mutations for selecting/prioritizing anticancer treatment, including cytotoxic chemotherapy and targeted agents, is unknown at this time. This cell line is wild type for BRAF, PTEN c-KIT, and CDK4.